{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24","upperLimit":"71","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"The percentage of PFS12 successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent confidence intervals for the true success proportion will be calculated according to the exact binomial method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Disease progression in evaluable patients will be defined as one or more of the following:\n\n* Any new disease and/or clear progression of evaluable disease; OR\n* 2 fold elevation in CA-125 from its lowest level (either initial level or nadir, whichever is lowest, since study enrollment) combined with CA-125 elevation confirmed by re-assay at any time.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Everolimus and Letrozole)"}],"paramType":"NUMBER","populationDescription":"All evaluable patients","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Percentage of Patients Alive and Progression Free Survival at 12 Weeks","type":"PRIMARY","unitOfMeasure":"percentage of patients"}